Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.47 |
| ▸ | RARA | P10276 | 8/20 | 0.47 |
| ▸ | RARG | P13631 | 8/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | BLVRB | P30043 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387781 | 0.91 | MAOA (0.46) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL389070 | 0.86 | RARA (0.51) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL388748 | 0.85 | CHUK (0.55) | RARBHDAC6CHUKTXNRD1NOX4 | |
| SCHEMBL388121 | 0.82 | S1PR1 (0.52) | CHUKTXNRD1NOX4IP6K1IP6K3 | |
| SCHEMBL389382 | 0.82 | NPC1 (0.67) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL386932 | 0.82 | NPC1 (0.55) | HDAC6MAOABLVRBCHUKTXNRD1 | |
| SCHEMBL15632593 | 0.81 | NPC1 (0.56) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL389932 | 0.79 | MAOA (0.50) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL387784 | 0.79 | MAOA (0.48) | RARBRARARARGHDAC6MAOA | |
| SCHEMBL1709948 | 0.78 | S1PR1 (0.43) | RARBCHUKTXNRD1NOX4IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | claimed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | UPF1, RIOX2, RNMT | RARB 1444/4885RARA 2516/4885RARG 2843/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | RARB 2954/4885RARA 3522/4885RARG 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.